SCHEMBL13764319

SCHEMBL13764319

CC(C)(C)OC(=O)N1CCC[C@H](Nc2nccn3cc(-c4ccc(Cl)cc4)nc23)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.47
▸ CNR2 P34972 2/20 0.47
▸ USP30 Q70CQ3 4/20 0.46
▸ ANO1 Q5XXA6 2/20 0.46
▸ HDAC4 P56524 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ PIM1 P11309 2/20 0.43
▸ PIM2 Q9P1W9 2/20 0.43
▸ ALOX5 P09917 1/20 0.42
▸ PIK3CD O00329 1/20 0.42
▸ CHEK1 O14757 3/20 0.41
▸ MAPKAPK2 P49137 3/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ CSNK1D P48730 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13776788 0.86 USP30 (0.50) USP30HDAC4HDAC6PIM1PIM2
SCHEMBL13776787 0.85 USP30 (0.53) USP30ANO1HDAC4HDAC6PIM1
SCHEMBL13776782 0.84 CHEK1 (0.49) CNR1CNR2USP30ANO1HDAC4
SCHEMBL13764318 0.84 CHEK1 (0.49) CNR1CNR2USP30ANO1HDAC4
SCHEMBL13764317 0.82 CHEK1 (0.47) CNR1CNR2USP30ANO1HDAC4
SCHEMBL31227119 0.78 ANO1 (0.51) CNR1CNR2USP30ANO1HDAC4
SCHEMBL21598927 0.76 POLB (0.50) CNR1CNR2USP30ANO1PIM1
SCHEMBL16177330 0.76 POLB (0.50) CNR1CNR2USP30ANO1PIM1
SCHEMBL16177328 0.76 POLB (0.50) CNR1CNR2USP30ANO1PIM1
SCHEMBL13434252 0.75 ALDH1A1 (0.58) CNR1CNR2USP30ANO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2009-07-09 — — US disclosed
US-7557104-B2 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-07-07 — — US disclosed
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2008-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS CHEK1, CHEK2, CDKN1A CNR1 2724/4885CNR2 2858/4885USP30 1066/4885
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS CHEK1, CHEK2, CDKN1A CNR1 2724/4885CNR2 2858/4885USP30 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback